BioLineRx Reports Successful Top-Line Results in Phase 2 Trial for AML

BioLineRx (NASDAQ/TASE: BLRX) announced today positive top-line results from BL-8040’s Phase 2 clinical trial in relapsed or refractory acute myeloid leukemia . Data also identify a potential biomarker for future selection of BL-8040-responsive AML patients